{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:04:49Z","timestamp":1793228689937,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Endosc"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00464-023-10269-6","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T18:02:21Z","timestamp":1689357741000},"page":"7980-7990","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term potassium-competitive acid blockers administration causes microbiota changes in rats"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9053-6313","authenticated-orcid":false,"given":"Haythem","family":"Najah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo C. L.","family":"Edelmuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Riascos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Grier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala","family":"Al Asadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques A.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl V.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan M.","family":"Finnerty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Thomas J.","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasa","family":"Zarnegar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,14]]},"reference":[{"key":"10269_CR1","doi-asserted-by":"publisher","first-page":"S226","DOI":"10.1097\/MCG.0b013e31803233b7","volume":"41","author":"G Sachs","year":"2007","unstructured":"Sachs G, Shin JM, Vagin O, Lambrecht N, Yakubov I, Munson K (2007) The gastric H, K atpase as a drug target: past, present, and future. J Clin Gastroenterol 41:S226\u2013S242. https:\/\/doi.org\/10.1097\/MCG.0b013e31803233b7","journal-title":"J Clin Gastroenterol"},{"key":"10269_CR2","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1007\/s10620-010-1209-2","volume":"55","author":"WD Chey","year":"2010","unstructured":"Chey WD, Mody RR, Izat E (2010) Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement? Dig Dis Sci 55:3415\u20133422. https:\/\/doi.org\/10.1007\/s10620-010-1209-2","journal-title":"Dig Dis Sci"},{"key":"10269_CR3","doi-asserted-by":"publisher","first-page":"97688","DOI":"10.1371\/journal.pone.0097688","volume":"9","author":"H-J Luo","year":"2014","unstructured":"Luo H-J, Deng W-Q, Zou K (2014) Protonated form: the potent form of potassium-competitive acid blockers. PLoS ONE 9:97688. https:\/\/doi.org\/10.1371\/journal.pone.0097688","journal-title":"PLoS ONE"},{"key":"10269_CR4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s11894-010-0149-5","volume":"12","author":"G Sachs","year":"2010","unstructured":"Sachs G, Shin JM, Hunt R (2010) Novel approaches to inhibition of gastric acid secretion. Curr Gastroenterol Rep 12:437\u2013447. https:\/\/doi.org\/10.1007\/s11894-010-0149-5","journal-title":"Curr Gastroenterol Rep"},{"key":"10269_CR5","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1124\/jpet.111.185314","volume":"339","author":"JM Shin","year":"2011","unstructured":"Shin JM, Inatomi N, Munson K, Strugatsky D, Tokhtaeva E, Vagin O, Sachs G (2011) Characterization of a novel potassium-competitive acid blocker of the Gastric H, K-ATPase, 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1 H-pyrrol-3-yl]-N-ethylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther 339:412\u2013420. https:\/\/doi.org\/10.1124\/jpet.111.185314","journal-title":"J Pharmacol Exp Ther"},{"key":"10269_CR6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40265-015-0368-z","volume":"75","author":"KP Garnock-Jones","year":"2015","unstructured":"Garnock-Jones KP (2015) Vonoprazan: first global approval. Drugs 75:439\u2013443. https:\/\/doi.org\/10.1007\/s40265-015-0368-z","journal-title":"Drugs"},{"key":"10269_CR7","doi-asserted-by":"publisher","first-page":"4815","DOI":"10.2147\/DDDT.S276704","volume":"14","author":"F Chen","year":"2020","unstructured":"Chen F, Jiang H, Xu J, Wang S, Meng D, Geng P, Dai D, Zhou Q, Zhou Y (2020) In vitro and in vivo rat model assessments of the effects of vonoprazan on the pharmacokinetics of venlafaxine. DDDT 14:4815\u20134824. https:\/\/doi.org\/10.2147\/DDDT.S276704","journal-title":"DDDT"},{"key":"10269_CR8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nature11550","volume":"489","author":"CA Lozupone","year":"2012","unstructured":"Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R (2012) Diversity, stability and resilience of the human gut microbiota. Nature 489:220\u2013230. https:\/\/doi.org\/10.1038\/nature11550","journal-title":"Nature"},{"key":"10269_CR9","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/ni.2608","volume":"14","author":"N Kamada","year":"2013","unstructured":"Kamada N, Chen GY, Inohara N, N\u00fa\u00f1ez G (2013) Control of pathogens and pathobionts by the gut microbiota. Nat Immunol 14:685\u2013690. https:\/\/doi.org\/10.1038\/ni.2608","journal-title":"Nat Immunol"},{"key":"10269_CR10","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/4441022a","volume":"444","author":"RE Ley","year":"2006","unstructured":"Ley RE, Turnbaugh PJ, Klein S, Gordon JI (2006) Human gut microbes associated with obesity. Nature 444:1022\u20131023. https:\/\/doi.org\/10.1038\/4441022a","journal-title":"Nature"},{"key":"10269_CR11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature10213","volume":"474","author":"AL Kau","year":"2011","unstructured":"Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI (2011) Human nutrition, the gut microbiome and the immune system. Nature 474:327\u2013336. https:\/\/doi.org\/10.1038\/nature10213","journal-title":"Nature"},{"key":"10269_CR12","doi-asserted-by":"publisher","first-page":"733992","DOI":"10.3389\/fcimb.2022.733992","volume":"12","author":"P Qiu","year":"2022","unstructured":"Qiu P, Ishimoto T, Fu L, Zhang J, Zhang Z, Liu Y (2022) The gut microbiota in inflammatory bowel disease. Front Cell Infect Microbiol 12:733992. https:\/\/doi.org\/10.3389\/fcimb.2022.733992","journal-title":"Front Cell Infect Microbiol"},{"key":"10269_CR13","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.3390\/metabo12111064","volume":"12","author":"M Kandpal","year":"2022","unstructured":"Kandpal M, Indari O, Baral B, Jakhmola S, Tiwari D, Bhandari V, Pandey RK, Bala K, Sonawane A, Jha HC (2022) Dysbiosis of gut microbiota from the perspective of the gut-brain axis: role in the provocation of neurological disorders. Metabolites 12:1064. https:\/\/doi.org\/10.3390\/metabo12111064","journal-title":"Metabolites"},{"key":"10269_CR14","doi-asserted-by":"publisher","first-page":"1040991","DOI":"10.3389\/fphys.2022.1040991","volume":"13","author":"S Mei","year":"2022","unstructured":"Mei S, Deng Z, Chen Y, Ning D, Guo Y, Fan X, Wang R, Meng Y, Zhou Q, Tian X (2022) Dysbiosis: the first hit for digestive system cancer. Front Physiol 13:1040991. https:\/\/doi.org\/10.3389\/fphys.2022.1040991","journal-title":"Front Physiol"},{"key":"10269_CR15","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1124\/jpet.111.179556","volume":"337","author":"Y Hori","year":"2011","unstructured":"Hori Y, Matsukawa J, Takeuchi T, Nishida H, Kajino M, Inatomi N (2011) A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther 337:797\u2013804. https:\/\/doi.org\/10.1124\/jpet.111.179556","journal-title":"J Pharmacol Exp Ther"},{"key":"10269_CR16","first-page":"1","volume":"15","author":"A Blanco-Miguez","year":"2022","unstructured":"Blanco-Miguez A, Beghini F, Cumbo F, McIver LJ, Thompson KN, Zolfo M, Manghi P, Dubois L, Huang KD, Thomas AM, Piccinno G, Piperni E, Pun\u010doch\u00e1\u0159 M, Valles-Colomer M, Tett A, Giordano F, Davies R, Wolf J, Berry SE, Spector TD, Franzosa EA, Pasolli E, Asnicar F, Huttenhower C, Segata N (2022) Extending and improving metagenomic taxonomic profiling with uncharacterized species with MetaPhlAn 4. Bioinformatics 15:1\u20132","journal-title":"Bioinformatics"},{"key":"10269_CR17","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s41587-019-0209-9","volume":"37","author":"E Bolyen","year":"2019","unstructured":"Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, Alexander H, Alm EJ, Arumugam M, Asnicar F, Bai Y, Bisanz JE, Bittinger K, Brejnrod A, Brislawn CJ, Brown CT, Callahan BJ, Caraballo-Rodr\u00edguez AM, Chase J, Cope EK, Da Silva R, Diener C, Dorrestein PC, Douglas GM, Durall DM, Duvallet C, Edwardson CF, Ernst M, Estaki M, Fouquier J, Gauglitz JM, Gibbons SM, Gibson DL, Gonzalez A, Gorlick K, Guo J, Hillmann B, Holmes S, Holste H, Huttenhower C, Huttley GA, Janssen S, Jarmusch AK, Jiang L, Kaehler BD, Kang KB, Keefe CR, Keim P, Kelley ST, Knights D, Koester I, Kosciolek T, Kreps J, Langille MGI, Lee J, Ley R, Liu Y-X, Loftfield E, Lozupone C, Maher M, Marotz C, Martin BD, McDonald D, McIver LJ, Melnik AV, Metcalf JL, Morgan SC, Morton JT, Naimey AT, Navas-Molina JA, Nothias LF, Orchanian SB, Pearson T, Peoples SL, Petras D, Preuss ML, Pruesse E, Rasmussen LB, Rivers A, Robeson MS, Rosenthal P, Segata N, Shaffer M, Shiffer A, Sinha R, Song SJ, Spear JR, Swafford AD, Thompson LR, Torres PJ, Trinh P, Tripathi A, Turnbaugh PJ, Ul-Hasan S, van der Hooft JJJ, Vargas F, V\u00e1zquez-Baeza Y, Vogtmann E, von Hippel M, Walters W, Wan Y, Wang M, Warren J, Weber KC, Williamson CHD, Willis AD, Xu ZZ, Zaneveld JR, Zhang Y, Zhu Q, Knight R, Caporaso JG (2019) Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol 37:852\u2013857. https:\/\/doi.org\/10.1038\/s41587-019-0209-9","journal-title":"Nat Biotechnol"},{"key":"10269_CR18","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1038\/s41467-020-17041-7","volume":"11","author":"H Lin","year":"2020","unstructured":"Lin H, Peddada SD (2020) Analysis of compositions of microbiomes with bias correction. Nat Commun 11:3514. https:\/\/doi.org\/10.1038\/s41467-020-17041-7","journal-title":"Nat Commun"},{"key":"10269_CR19","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1038\/s41467-018-05184-7","volume":"9","author":"MA Jackson","year":"2018","unstructured":"Jackson MA, Verdi S, Maxan M-E, Shin CM, Zierer J, Bowyer RCE, Martin T, Williams FMK, Menni C, Bell JT, Spector TD, Steves CJ (2018) Gut microbiota associations with common diseases and prescription medications in a population-based cohort. Nat Commun 9:2655. https:\/\/doi.org\/10.1038\/s41467-018-05184-7","journal-title":"Nat Commun"},{"key":"10269_CR20","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gutjnl-2015-310861","volume":"65","author":"MA Jackson","year":"2016","unstructured":"Jackson MA, Goodrich JK, Maxan M-E, Freedberg DE, Abrams JA, Poole AC, Sutter JL, Welter D, Ley RE, Bell JT, Spector TD, Steves CJ (2016) Proton pump inhibitors alter the composition of the gut microbiota. Gut 65:749\u2013756. https:\/\/doi.org\/10.1136\/gutjnl-2015-310861","journal-title":"Gut"},{"key":"10269_CR21","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nature15766","volume":"528","author":"K Forslund","year":"2015","unstructured":"MetaHIT consortium, Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, Prifti E, Vieira-Silva S, Gudmundsdottir V, Krogh Pedersen H, Arumugam M, Kristiansen K, Yvonne Voigt A, Vestergaard H, Hercog R, Igor Costea P, Roat Kultima J, Li J, J\u00f8rgensen T, Levenez F, Dore J, Bj\u00f8rn Nielsen H, Brunak S, Raes J, Hansen T, Wang J, Dusko Ehrlich S, Bork P, Pedersen O (2015) Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528:262\u2013266. https:\/\/doi.org\/10.1038\/nature15766","journal-title":"Nature"},{"key":"10269_CR22","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1073\/pnas.1000087107","volume":"108","author":"L Dethlefsen","year":"2011","unstructured":"Dethlefsen L, Relman DA (2011) Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci USA 108:4554\u20134561. https:\/\/doi.org\/10.1073\/pnas.1000087107","journal-title":"Proc Natl Acad Sci USA"},{"key":"10269_CR23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/19490976.2017.1284732","volume":"8","author":"F Imhann","year":"2017","unstructured":"Imhann F, Vich Vila A, Bonder MJ, Lopez Manosalva AG, Koonen DPY, Fu J, Wijmenga C, Zhernakova A, Weersma RK (2017) The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. Gut Microbes 8:351\u2013358. https:\/\/doi.org\/10.1080\/19490976.2017.1284732","journal-title":"Gut Microbes"},{"key":"10269_CR24","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1007\/s10620-018-5122-4","volume":"63","author":"M Hojo","year":"2018","unstructured":"Hojo M, Asahara T, Nagahara A, Takeda T, Matsumoto K, Ueyama H, Matsumoto K, Asaoka D, Takahashi T, Nomoto K, Yamashiro Y, Watanabe S (2018) Gut Microbiota Composition Before and After Use of Proton Pump Inhibitors. Dig Dis Sci 63:2940\u20132949. https:\/\/doi.org\/10.1007\/s10620-018-5122-4","journal-title":"Dig Dis Sci"},{"key":"10269_CR25","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","volume":"65","author":"F Imhann","year":"2016","unstructured":"Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, Tigchelaar EF, Jankipersadsing SA, Cenit MC, Harmsen HJM, Dijkstra G, Franke L, Xavier RJ, Jonkers D, Wijmenga C, Weersma RK, Zhernakova A (2016) Proton pump inhibitors affect the gut microbiome. Gut 65:740\u2013748. https:\/\/doi.org\/10.1136\/gutjnl-2015-310376","journal-title":"Gut"},{"key":"10269_CR26","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/s41598-020-57612-8","volume":"10","author":"Y-CSH Yang","year":"2020","unstructured":"Yang Y-CSH, Chang H-W, Lin I-H, Chien L-N, Wu M-J, Liu Y-R, Chu PG, Xie G, Dong F, Jia W, Chang VHS, Yen Y (2020) Long-term proton pump inhibitor administration caused physiological and microbiota changes in rats. Sci Rep 10:866. https:\/\/doi.org\/10.1038\/s41598-020-57612-8","journal-title":"Sci Rep"},{"key":"10269_CR27","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1126\/science.aad3369","volume":"352","author":"A Zhernakova","year":"2016","unstructured":"Zhernakova A, Kurilshikov A, Bonder MJ, Tigchelaar EF, Schirmer M, Vatanen T, Mujagic Z, Vila AV, Falony G, Vieira-Silva S, Wang J, Imhann F, Brandsma E, Jankipersadsing SA, Joossens M, Cenit MC, Deelen P, Swertz MA, LifeLines cohort study, Weersma RK, Feskens EJM, Netea MG, Gevers D, Jonkers D, Franke L, Aulchenko YS, Huttenhower C, Raes J, Hofker MH, Xavier RJ, Wijmenga C, Fu J (2016) Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 352:565\u2013569. https:\/\/doi.org\/10.1126\/science.aad3369","journal-title":"Science"},{"key":"10269_CR28","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/apt.13461","volume":"43","author":"K Ashida","year":"2016","unstructured":"Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, Umegaki E, Iwakiri K (2016) Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 43:240\u2013251. https:\/\/doi.org\/10.1111\/apt.13461","journal-title":"Aliment Pharmacol Ther"},{"key":"10269_CR29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1124\/jpet.110.170274","volume":"335","author":"Y Hori","year":"2010","unstructured":"Hori Y, Imanishi A, Matsukawa J, Tsukimi Y, Nishida H, Arikawa Y, Hirase K, Kajino M, Inatomi N (2010) 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1 H -pyrrol-3-yl]- N-methylmethanamine Monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 335:231\u2013238. https:\/\/doi.org\/10.1124\/jpet.110.170274","journal-title":"J Pharmacol Exp Ther"},{"key":"10269_CR30","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.4014\/jmb.1709.09027","volume":"27","author":"B-R Kim","year":"2017","unstructured":"Kim B-R, Shin J, Guevarra RB, Lee JH, Kim DW, Seol K-H, Lee J-H, Kim HB, Isaacson RE (2017) Deciphering diversity indices for a better understanding of microbial communities. J Microbiol Biotechnol 27:2089\u20132093. https:\/\/doi.org\/10.4014\/jmb.1709.09027","journal-title":"J Microbiol Biotechnol"},{"key":"10269_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12923","author":"Y Hu","year":"2022","unstructured":"Hu Y, Xu X, Ouyang Y, He C, Li N, Xie C, Peng C, Zhu Z, Xie Y, Shu X, Lu N, Zhu Y (2022) Analysis of oral microbiota alterations induced by Helicobacter pylori infection and vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication. Helicobacter. https:\/\/doi.org\/10.1111\/hel.12923","journal-title":"Helicobacter"},{"key":"10269_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12851","author":"S Suzuki","year":"2021","unstructured":"Suzuki S, Gotoda T, Takano C, Horii T, Sugita T, Ogura K, Ichijima R, Kusano C, Ikehara H (2021) Long term impact of vonoprazan-based Helicobacter pylori treatment on gut microbiota and its relation to post-treatment body weight changes. Helicobacter. https:\/\/doi.org\/10.1111\/hel.12851","journal-title":"Helicobacter"},{"key":"10269_CR33","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41598-020-80802-3","volume":"11","author":"T Kakiuchi","year":"2021","unstructured":"Kakiuchi T, Yamamoto K, Imamura I, Hashiguchi K, Kawakubo H, Yamaguchi D, Fujioka Y, Okuda M (2021) Gut microbiota changes related to Helicobacter pylori eradication with vonoprazan containing triple therapy among adolescents: a prospective multicenter study. Sci Rep 11:755. https:\/\/doi.org\/10.1038\/s41598-020-80802-3","journal-title":"Sci Rep"},{"key":"10269_CR34","doi-asserted-by":"publisher","first-page":"8905","DOI":"10.3748\/wjg.v22.i40.8905","volume":"22","author":"M Zhang","year":"2016","unstructured":"Zhang M, Yang X-J (2016) Effects of a high fat diet on intestinal microbiota and gastrointestinal diseases. WJG 22:8905. https:\/\/doi.org\/10.3748\/wjg.v22.i40.8905","journal-title":"WJG"},{"key":"10269_CR35","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1111\/jgh.15572","volume":"36","author":"T Horii","year":"2021","unstructured":"Horii T, Suzuki S, Takano C, Shibuya H, Ichijima R, Kusano C, Ikehara H, Gotoda T (2021) Lower impact of vonoprazan\u2013amoxicillin dual therapy on gut microbiota for Helicobacter pylori eradication. J Gastro Hepatol 36:3314\u20133321. https:\/\/doi.org\/10.1111\/jgh.15572","journal-title":"J Gastro Hepatol"},{"key":"10269_CR36","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3390\/jcm8040451","volume":"8","author":"I Cornejo-Pareja","year":"2019","unstructured":"Cornejo-Pareja I, Mart\u00edn-N\u00fa\u00f1ez G, Roca-Rodr\u00edguez M, Cardona F, Coin-Arag\u00fcez L, S\u00e1nchez-Alcoholado L, Guti\u00e9rrez-Repiso C, Mu\u00f1oz-Garach A, Fern\u00e1ndez-Garc\u00eda J, Moreno-Indias I, Tinahones F (2019) H. pylori eradication treatment alters gut microbiota and GLP-1 secretion in humans. JCM 8:451. https:\/\/doi.org\/10.3390\/jcm8040451","journal-title":"JCM"},{"key":"10269_CR37","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/mds.26069","volume":"30","author":"F Scheperjans","year":"2015","unstructured":"Scheperjans F, Aho V, Pereira PAB, Koskinen K, Paulin L, Pekkonen E, Haapaniemi E, Kaakkola S, Eerola-Rautio J, Pohja M, Kinnunen E, Murros K, Auvinen P (2015) Gut microbiota are related to Parkinson\u2019s disease and clinical phenotype. Mov Disord 30:350\u2013358. https:\/\/doi.org\/10.1002\/mds.26069","journal-title":"Mov Disord"},{"key":"10269_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2020.01.102","volume":"266","author":"K Sanada","year":"2020","unstructured":"Sanada K, Nakajima S, Kurokawa S, Barcel\u00f3-Soler A, Ikuse D, Hirata A, Yoshizawa A, Tomizawa Y, Salas-Valero M, Noda Y, Mimura M, Iwanami A, Kishimoto T (2020) Gut microbiota and major depressive disorder: A systematic review and meta-analysis. J Affect Disord 266:1\u201313. https:\/\/doi.org\/10.1016\/j.jad.2020.01.102","journal-title":"J Affect Disord"},{"key":"10269_CR39","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3389\/fpsyt.2020.00541","volume":"11","author":"ZA Barandouzi","year":"2020","unstructured":"Barandouzi ZA, Starkweather AR, Henderson WA, Gyamfi A, Cong XS (2020) Altered Composition of gut microbiota in depression: a systematic review. Front Psychiatry 11:541. https:\/\/doi.org\/10.3389\/fpsyt.2020.00541","journal-title":"Front Psychiatry"},{"key":"10269_CR40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.4161\/gmic.2.3.16333","volume":"2","author":"AE Reeves","year":"2011","unstructured":"Reeves AE, Theriot CM, Bergin IL, Huffnagle GB, Schloss PD, Young VB (2011) The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection. Gut Microbes 2:145\u2013158. https:\/\/doi.org\/10.4161\/gmic.2.3.16333","journal-title":"Gut Microbes"}],"container-title":["Surgical Endoscopy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-023-10269-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00464-023-10269-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-023-10269-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T19:04:12Z","timestamp":1711134252000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00464-023-10269-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10269"],"URL":"https:\/\/doi.org\/10.1007\/s00464-023-10269-6","relation":{},"ISSN":["0930-2794","1432-2218"],"issn-type":[{"value":"0930-2794","type":"print"},{"value":"1432-2218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,14]]},"assertion":[{"value":"30 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Rasa Zarnegar works as a consultant for Bard (BD). Drs. Haythem Najah, Rodrigo C.L. Edelmuth, Maria Cristina Riascos, Alex Grier, Hala Al Asadi, Jacques A. Greenberg, Ileana Miranda, Carl V. Crawford, Brendan M. Finnerty, and Thomas J. Fahey III have no conflicts of interest or financial ties to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}